EDIT vs VRTX
EDIT and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEditas Medicine, Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $258.47M | $119.40B |
| P/E (TTM) | — | 27.9 |
| P/B | — | 6.17 |
| P/S | 6.4x | 9.9x |
| Revenue | — | $12.22B(TTM) |
| Revenue growth (YoY) | 25.4% | 8.9% |
| Net income | — | $4.34B(TTM) |
| Earnings growth (YoY) | 32.5% | 838.1% |
| EPS, diluted | — | $16.85(TTM) |
| EBIT margin | -394.9% | 34.8% |
| ROE | -3631.1% | 20.4% |
| ROIC | — | 25.4% |
| 1y total return | +8.0% | +1.8% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: EDIT vs VRTX
| Metric | EDIT | VRTX |
|---|---|---|
| End value | $767 | $59.2K |
| Total return | -92.3% | +492.2% |
| CAGR | -22.0% | +18.8% |
| Volatility | 83.4% | 33.0% |
| Sharpe | 0.06 | 0.57 |
| Sortino | 0.09 | 0.84 |
| Max drawdown | -98.9% | -41.6% |
Based on 2600 common trading days, 2016-03-31 → 2026-08-03 · risk-free 3.91% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)